about
Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An updateBenefit-risk assessment of golimumab in the treatment of refractory ulcerative colitisImmune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: effects of combined therapy with immunosuppressants.Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon.Extraintestinal manifestations in inflammatory bowel disease.Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study.Gut Microbiota: A Key Modulator of Intestinal Healing in Inflammatory Bowel Disease.Efficacy and Mechanisms of Action of Fecal Microbiota Transplantation in Ulcerative Colitis: Pitfalls and Promises From a First Meta-Analysis.Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation.Biological therapies for inflammatory bowel disease: research drives clinics.Predictive value of the Diverticular Inflammation and Complication Assessment (DICA) endoscopic classification on the outcome of diverticular disease of the colon: An international study.Infliximab does not increase colonic cancer risk associated to murine chronic colitis.Venous thromboembolism in patients with inflammatory bowel disease: focus on prevention and treatment.Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease.Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases.Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future.Biologic therapies in ulcerative colitis: primi inter pares?Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study.Prevalence of factor V Leiden and the G20210A prothrombin-gene mutation in inflammatory bowel disease.FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents.Endoscopic findings and clinical patterns are not useful for distinguishing low from high grade gastric MALT lymphoma.Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents.Inter-observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG-IBD).Helicobacter pylori CagA-positive strains affect oxygen free radicals generation by gastric mucosa.Gastric mucosa-associated lymphoid tissue in autoimmune thyroid diseases.Role of Helicobacter pylori CagA+ infection in determining oxidative DNA damage in gastric mucosa.Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis.Low-dose omeprazole plus clarithromycin and either tinidazole or amoxycillin for Helicobacter pylori infection.Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease.Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab.Locally injected Infliximab ameliorates murine DSS colitis: differences in serum and intestinal levels of drug between healthy and colitic mice.Disappearance of gastric mucosa-associated lymphoid tissue in coeliac patients after gluten withdrawal.Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting.Differentiation Affects the Release of Exosomes from Colon Cancer Cells and Their Ability to Modulate the Behavior of Recipient Cells.Direct effect of infliximab on intestinal mucosa sustains mucosal healing: exploring new mechanisms of action.Anti-TNF-α-induced psoriasiform lesions in IBD: an abnormal immune activation or a 'patchy cutaneous' immune suppression?Training Programs on Endoscopic Scoring Systems for Inflammatory Bowel Disease Lead to a Significant Increase in Interobserver Agreement Among Community Gastroenterologists.Acute cytomegalovirus infection as a possible trigger for pulmonary thromboembolism in a patient with steroid-refractory ulcerative colitis.Prevalence of the K469E polymorphism of intercellular adhesion molecule 1 gene in Italian patients with inflammatory bowel disease.Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year
P50
Q26746916-5844CD25-2CE5-43CA-A4D9-DB5B9110DC05Q26764801-953F16F1-8AC5-48E9-A640-615140243F0EQ30417659-C62A8473-BC90-4320-B669-56DCC4ACA006Q34486456-E2F6802C-52BE-4B26-A67F-4D0F6C13288DQ34488386-CB8DDAF9-6EF6-4BD8-B0E0-36ACDE4DC651Q35233808-456F817A-92E9-45D2-8669-F80CB7D1AE72Q35973916-FB18147E-8B8E-4096-83E3-6BCC3BD185DCQ35997871-2E69FF6E-C9C4-4E9A-827B-33DA972913A6Q36259898-991A9953-5D59-4F81-B7FD-5A5CC22B87DAQ36536248-1BC17628-DBBA-4EC4-9532-5FF023035B4AQ37148670-D81440F6-18AC-4A8F-8CF6-91FC07FFCA8CQ37444240-5788B9DE-004C-4123-9DF2-9CB58CDAF85FQ37660669-15924ACC-0FB0-458A-AC01-8946CB9779E3Q38085904-D7A0B3E8-D225-468F-BDEA-3C8EE7B4FFCCQ38462602-E6F39CCD-F317-4DA0-876E-A2946DC9FFBCQ38816194-0723F220-94C7-4893-882D-3AF47E6265C7Q38845697-84BA6D37-2263-437F-8C33-D0430421AB7DQ41520678-308F5C35-96B2-4429-A16F-FC9E1DAD2179Q41754449-49D3EBD1-D099-4261-A330-D4924B352E31Q41919734-FAB7943D-2F44-47DF-A160-69A3FBB25F5DQ42747510-0D8F703E-62EF-4103-9A14-B7A5C5007D48Q42978890-897F8DCA-25DB-4F42-ACFE-2118524F93E2Q43407161-12FD301E-8C59-42BB-973D-43F1563F66DAQ43577160-98D0C562-0F4E-4217-A03B-8666F8ABF625Q43772119-97842AD1-BF69-46B4-89FB-F75FB3E8E841Q43979348-E6C79ECE-5C76-4821-B5E3-66DBC93D4EEEQ44104683-06C07969-B6C0-4C35-A2DA-5F22536C5DE4Q45278815-D88C4F0A-6FD9-4EDA-B2B2-9FEC90F55692Q46397604-440B6D73-514D-47E2-B62E-62FD88A8A889Q47118783-8BACDFBE-71C1-4FA4-82E7-B76743B2C435Q47869617-FD8F1EC3-9420-4450-ADC2-5B6BFE19F936Q48031882-FB191E8D-BD69-4ECF-A1D7-936270AEC8A9Q48662272-9896292B-9D94-48F2-AFCA-FFF673B0FAF6Q50582728-8EE6EF29-E2B2-43A4-83D5-3B49273B94C7Q52887574-34B3283C-870A-4D84-9D7F-C2086DAFF21BQ53082441-9CD3D479-92E9-4990-A0DC-D5A7A56A3A36Q53242847-260546F2-CFF2-476D-A795-088397C762B6Q54374050-7C74B65C-A74F-430C-A528-B7D509C19480Q54704104-620BEEB0-D776-4653-8F51-E031C0587206Q57707301-AB250C1A-0777-425B-88ED-B7030DD952B6
P50
description
researcher
@en
wetenschapper
@nl
name
A Papa
@en
A Papa
@nl
type
label
A Papa
@en
A Papa
@nl
prefLabel
A Papa
@en
A Papa
@nl
P106
P31
P496
0000-0002-4186-7298